Skip to main content
. 2020 Nov 2;6(4):00566-2020. doi: 10.1183/23120541.00566-2020

TABLE 3.

Summary demographics and findings of all recruited children. Demographics, background, investigation results, asthma control scores and respiratory treatments for all participants

Registry variables Number of patients
Age
 6–11 years; mean±sem 26 (32%); 9.37±0.31 years
 ≥12 years; mean±sem 54 (68%); 14.70±0.22 years
 Overall mean±sem 12.96±0.33 years
Sex male/female 49 (61%)/ 31 (39%)
Ethnicity Caucasians: 60 (75%);
South-east Asians: 8 (10%);
Black: 8 (10%);
Mixed: 4 (5%)
Parental history Asthma: 38;
Atopic eczema: 17;
Allergic rhinitis: 33
Smoking history Personal smoking: 2;
Paternal smoking: 41;
Maternal smoking: 12
Allergic asthma
 Skin prick tests Positive for perennial aeroallergen: 31;
Positive for food allergen: 14
 Specific IgE Positive for perennial aeroallergen: 42;
Positive for food allergen: 16
Highest blood eosinophils (cells·µL-1) in the 6 months prior to enrolment ≥150: 41;
<150: 11;
Not recently assessed: 28
Highest blood IgE (IU·mL−1) in the 6 months prior to enrolment ≥700: 21;
30–699: 26;
<30: 5;
Not recently assessed: 28
Highest FeNO (ppb) in the 6 months prior to enrolment >35: 28;
20–35: 11;
<20: 16;
Not recently assessed: 25
Asthma control
 ACT score
  Median (IQR) ACT 20 (16–23)
  Control by ACT Poor control (<20): 26;
Good control (≥20): 31;
Not assessed: 23
 GINA asthma control Uncontrolled: 25;
Partly controlled: 23;
Well controlled: 32
 ≥2 exacerbations per year Total:49;
With good ACT/GINA control: 12
 Suboptimal control by SPACE definition 62
Best FEV1 (% predicted) in the 6 months prior to enrolment <70%: 7;
70–79%: 10;
80–89%: 16;
≥90%: 46;
Not recently assessed: 1

Data are presented as n (%) or n, unless otherwise stated. FeNO: exhaled nitric oxide fraction; ACT: asthma control test; IQR: interquartile range; GINA: Global Initiative for Asthma; SPACE: Severe Paediatric Asthma Collaborative in Europe; FEV1: forced expiratory volume in 1 s.